PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

This clinical study is aiming to determine the safest doses and schedule for the combination of two drugs named palbociclib and avelumab. The study will also be investigating how effective the combination is for a subgroup of breast cancer patients whose cancer expresses the androgen receptor (AR) but not the oestrogen (hormone) or HER2 receptors. Palbociclib is a drug used in routine care for hormone-receptor (HR) positive and HER2 negative advanced breast cancer, the most common subtype of breast cancer. It is possible that the combination of palbociclib and avelumab will be a more effecti

Trial Details

NCT ID
NCT04360941
Phase
PHASE1
Sponsor
Royal Marsden NHS Foundation Trust
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Palbociclib
  • Avelumab
Locations (sample)
  • Manchester, Greater Manchester, United Kingdom|53.48095,-2.23743
  • Cambridge, United Kingdom|52.2,0.11667
  • Glasgow, United Kingdom|55.86515,-4.25763
  • Leicester, United Kingdom|52.6386,-1.13169
  • London, United Kingdom|51.50853,-0.12574

Key Eligibility Criteria

  • Patients with recurrent inoperable locally advanced or metastatic breast cancer.
  • Previously treated with at least one prior line of chemotherapy for advanced disease, but no more than two prior lines of chemotherapy for advanced…
  • Measurable disease (RECIST 1.1)
  • Haematological and biochemical indices within the ranges stated in the study protocol. These measurements must be performed within one week (Day -7…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →